Coherus Biosciences Stock Fundamentals
| CHRS Stock | USD 1.21 0.12 11.01% |
Coherus BioSciences fundamentals help investors to digest information that contributes to Coherus BioSciences' financial success or failures. It also enables traders to predict the movement of Coherus Stock. The fundamental analysis module provides a way to measure Coherus BioSciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Coherus BioSciences stock.
At this time, Coherus BioSciences' Interest Expense is comparatively stable compared to the past year. Gross Profit is likely to gain to about 141.2 M in 2024, whereas Selling General Administrative is likely to drop slightly above 100.1 M in 2024. Coherus | Select Account or Indicator |
Coherus BioSciences Company Operating Margin Analysis
Coherus BioSciences' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Coherus BioSciences Operating Margin | (0.09) % |
Most of Coherus BioSciences' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Coherus BioSciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Coherus Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Coherus BioSciences has an Operating Margin of -0.0902%. This is 99.74% lower than that of the Biotechnology sector and 99.92% lower than that of the Health Care industry. The operating margin for all United States stocks is 98.36% lower than that of the firm.
Coherus BioSciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Coherus BioSciences's current stock value. Our valuation model uses many indicators to compare Coherus BioSciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Coherus BioSciences competition to find correlations between indicators driving Coherus BioSciences's intrinsic value. More Info.Coherus BioSciences is rated below average in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At this time, Coherus BioSciences' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Coherus BioSciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Coherus Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Coherus BioSciences' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Coherus BioSciences could also be used in its relative valuation, which is a method of valuing Coherus BioSciences by comparing valuation metrics of similar companies.Coherus BioSciences is currently under evaluation in operating margin category among its peers.
Coherus BioSciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Coherus BioSciences from analyzing Coherus BioSciences' financial statements. These drivers represent accounts that assess Coherus BioSciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Coherus BioSciences' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.3B | 1.2B | 1.2B | 614.8M | 313.6M | 518.3M | |
| Enterprise Value | 1.3B | 1.1B | 1.2B | 1.0B | 691.5M | 539.3M |
Coherus Fundamentals
| Return On Equity | -16.57 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 311.59 M | ||||
| Shares Outstanding | 115.21 M | ||||
| Shares Owned By Insiders | 1.39 % | ||||
| Shares Owned By Institutions | 70.09 % | ||||
| Number Of Shares Shorted | 31.51 M | ||||
| Price To Earning | 4.22 X | ||||
| Price To Book | 73.19 X | ||||
| Price To Sales | 0.46 X | ||||
| Revenue | 257.24 M | ||||
| Gross Profit | (58.4 M) | ||||
| EBITDA | (193.94 M) | ||||
| Net Income | (237.89 M) | ||||
| Cash And Equivalents | 275.48 M | ||||
| Cash Per Share | 3.54 X | ||||
| Total Debt | 480.84 M | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | (0.76) X | ||||
| Cash Flow From Operations | (174.88 M) | ||||
| Short Ratio | 11.95 X | ||||
| Earnings Per Share | (0.09) X | ||||
| Target Price | 6.5 | ||||
| Number Of Employees | 235 | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 139.41 M | ||||
| Total Asset | 629.6 M | ||||
| Retained Earnings | (1.58 B) | ||||
| Working Capital | 143.86 M | ||||
| Current Asset | 197.39 M | ||||
| Current Liabilities | 106.02 M | ||||
| Net Asset | 629.6 M |
About Coherus BioSciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Coherus BioSciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coherus BioSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coherus BioSciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -2.8 M | -2.7 M | |
| Total Revenue | 257.2 M | 172.9 M | |
| Cost Of Revenue | 162.8 M | 83.5 M | |
| Stock Based Compensation To Revenue | 0.17 | 0.16 | |
| Sales General And Administrative To Revenue | 0.80 | 0.76 | |
| Research And Ddevelopement To Revenue | 0.43 | 0.40 | |
| Revenue Per Share | 2.73 | 2.06 | |
| Ebit Per Revenue | (0.79) | (0.83) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.